您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 泌尿生殖系统及泌乳药物->前列腺疾病用药
处方药:处方药
包装规格: 0.5毫克/软胶囊 30软胶囊/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
葛兰素史克
生产厂家英文名:
GLAXOSMITHKLINE
该药品相关信息网址1:
http://en.wikipedia.org/wiki/Dutasteride
该药品相关信息网址2:
http://www.rxlist.com/avodart-drug.htm
原产地英文商品名:
AVODART 0.5mg/softgel 30softgel/box
原产地英文药品名:
DUTASTERIDE
中文参考商品译名:
适尿通 0.5毫克/软胶囊 30软胶囊/盒
中文参考药品译名:
度他雄胺
原产地国家批准上市年份:
2001/11/20
英文适应病症1:
Reduce severe symptoms of benign prostatic
英文适应病症2:
Reduce the risk of serious urinary tract to avoid lock
英文适应病症3:
Reduce the risk of prostate surgery
临床试验期:
完成
中文适应病症参考翻译1:
减缓严重的良性前列腺症状
中文适应病症参考翻译2:
减低严重尿路避锁的风险
中文适应病症参考翻译3:
减低前列腺手术的风险
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20107600314018.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文AVODART处方资料(仅供参考)

    2003年3月13日在西班牙的马德里- GlaxoSmithKline (GSK) 今天庆祝 Avodart (dutaster ide)的国际上市, 一种新的并且有效的减缓严重的良性前列腺症状的配方, 并且减低严重尿路避锁的风险及手术的风险.
    对于此药的发行上市, 英国Stevenage的Lister 医院的泌尿外科医师Tom McNicholas说 " 上市对于前列腺肿大的患者是一个好消息,因为此药提供患者一种有效的治疗选择, 它列出除了症状的控制更多的东西. 在超过两年的临床试验以经证明 Avodart不仅是安全的,并且能减低严重尿路避锁达57%,及前列腺手术达48%."
    Avodart 是一种新奇的5-alpha 还原酶阻档剂 (5-ARI), 它阻挡了type 1及 type 2 两种5-alpha 还原酶的异酵素(isoenzymes,这种酵素是负责将前列腺中的睪丸激素转化成dihydrotest osterone (DHT), DHT 是一种主要的造成前列腺增长及肥大的荷尔蒙原因. Avodart 显示了它在两周内对DHT压制的能力达90%并且最快在1个月就能缩小前列腺,在此研究持续使用两年以上的实验中还一直持续缩小前列腺的肥大情形.1
    欧洲泌尿科协会在马德里的年度会议新发表的资料更加强化了 5-ARIs做为前列腺肥大的一种治疗选择的地位.一个有4,500 病患参与的实验显示有使用 alpha-阻档剂者比起使用5ARI组挡剂者者有约两倍者还是有严重尿路避锁/导尿的经验 2   从此会议新发表的其它的资料显示用alpha-阻挡剂来治疗前列腺肥大并不能改变前列腺持续肥大化等复杂的相关症状的风险 3
    前列腺肥大是一种上了年纪的男人最常见的建康问题 .它是一种非应癌症性的前列腺体增大它通常会造成尿道缩小的症状. 前列腺肥大是一种累进性的疾病如果长期放任着不去治疗可能会造成更严重的问题如尿道闭锁或必须动手术.
    Avodart 是非常容易被人体所接受. 大体来说, 在临床试验中, 在被认证过的产品总结特征报告中最常见的负面结果是 阳萎 (6%), 性欲减退 (3.7%), 射精失调 (1.8%), 女乳化 (1.3%).

Dutasteride
Dutasteride (brand name Avodart) is a 5-alpha-reductase inhibitor that inhibits the conversion of testosterone into dihydrotestosterone (DHT). It is approved for the treatment of benign prostatic hyperplasia (BPH) and is prescribed off-label for the treatment of male pattern baldness (MPB). Avodart is manufactured and marketed by GlaxoSmithKline.

Classification and method of action
Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride, which is also approved for the treatment of benign prostatic hyperplasia (BPH), in addition to the treatment of male pattern baldness (MPB), belongs to this group of drugs.
Dutasteride inhibits both isoforms of 5-alpha reductase, Type I and Type II, whereas finasteride only inhibits Type II. There are no long-term randomized trials comparing the effects of dutasteride and finasteride in patients with BPH. The EPICS trial, a 12-month clinical study done by GlaxoSmithKline, demonstrated treatment with dutasteride and finasteride resulted in similar decreases in prostate volume, with numerically but not statistically significantly greater improvements in symptom scores for the dutasteride group. Finasteride is marketed by Merck under the trademark names Proscar (5 mg/day finasteride) for BPH and Propecia (1 mg/day finasteride) for MPB. Published data from controlled clinical trials demonstrated that 5 mg finasteride did not have better results than 1 mg for the treatment of MPB.

Uses
While dutasteride is only officially approved to treat enlargement of the prostate gland (at a dose of 0.5 mg/day), phase I and II clinical trials for dutasteride as a hair loss drug were also undertaken, but called off in late 2002. The reason the trials were called off is not publicly known. Industry sources speculate that Avodart would have been seen as too similar to Propecia (1 mg/day finasteride) to have proven itself profitable on the market as a hair loss treatment. However, phase II results indicated that dutasteride at both 0.5 mg and 2.5 mg/day generated a superior hair count to finasteride 5 mg at 12 and 24 weeks.

In a test area at 24 weeks, results showed:
Placebo - Minus 32.3 hairs
Finasteride 5 mg - 75.6 hairs
Dutasteride 0.1 mg - 78.5 hairs
Dutasteride 0.5 mg - 94.6 hairs
Dutasteride 2.5 mg - 109.6 hairs

In December 2006, GlaxoSmithKline started a new Phase III, six month study in Korea to test the safety, tolerability and effectiveness of a once-daily dose of dutasteride (0.5 mg) for the treatment of MPB in the vertex region of the scalp (types IIIv, IV and V on the Hamilton-Norwood scale). The study has been completed as of January 2009. The future impact that this study will have on the approval or disapproval by the U.S. Food and Drug Administration (FDA) of Avodart for the treatment of MPB in the United States is yet to be determined.

The REDUCE trial, a randomized controlled trial of 6,729 men comparing dutasteride to placebo for prevention of prostate cancer, found an overall reduction of 22% in the incidence of prostate cancer over 4 years. However, the reduction was entirely in Gleason grades 5 and 6 cancers, which are less life-threatening and often not treated. In Gleason grade 7-10, which are life-threatening, there was no reduction in cancer. According to an editorial, "Dutasteride and finasteride do not prevent prostate cancer but merely temporarily shrink tumors that have a low potential for being lethal." They may also delay diagnosis until prostate cancer is difficult to cure.

Side effects
Avodart 500 micrograms soft capsules (AU)Adverse events

Year 1
Placebo (n = 2158)
Impotence 3% - Decreased libido 2% - Ejaculation disorders <1% - Breast Disorders <1%
Avodart (n = 2167)
Impotence 6% - Decreased libido 4% - Ejaculation disorders 2% - Breast Disorders 1%

Year 2
Placebo (n = 1736 )
Impotence 1% - Decreased libido <1% - Ejaculation disorders <1% - Breast Disorders <1%
Avodart (n = 1744)
Impotence 2% - Decreased libido <1% - Ejaculation disorders <1% - Breast Disorders 1%

Teratogenic effect
The teratogenic effect from dutasteride is harmful to male children. Women who are pregnant should not handle the capsules, as inadvertent consumption could cause birth defects of the male fetus. The adverse effects would be similar to 5-alpha-reductase deficiency, where a developing male child is naturally deficient in 5-alpha reductase Type II, and thus unable to synthesize it. As dutasteride blocks the same process, developing males would have a DHT deficiency with its adverse effects as a result of the drug. Men should not donate blood while taking Avodart and for at least 6 months after treatment ends. Avodart can be carried in the blood and could cause birth defects if a pregnant women receives a transfusion with blood that contains dutasteride

See also
Finasteride
Dihydrotestosterone
Baldness treatments
Male pattern baldness
Benign prostatic hyperplasia

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20107600314018.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2013-08-18
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com